<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-275" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hydroxyurea Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jinna</surname>
            <given-names>Sruthi</given-names>
          </name>
          <aff>Beaumont Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khandhar</surname>
            <given-names>Paras B.</given-names>
          </name>
          <aff>Beaumont Health System</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sruthi Jinna declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Paras Khandhar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-275.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hydroxyurea is an antineoplastic agent used alone or in combination with other chemotherapeutic drugs or radiation in the treatment of resistant leukemias and carcinomas of the head and neck. It is also used to increase fetal hemoglobin concentration, thus reducing the frequency of severe crisis and reducing the necessity for blood transfusions in patients with sickle cell anemia. Despite its utility, hydroxyurea is an extremely toxic drug with a low therapeutic index. This activity reviews the etiology, presentation, evaluation, and management of hydroxyurea toxicity and the role of the interprofessional team in evaluating, diagnosing, and managing the condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the toxicokinetics of hydroxyurea toxicity.</p></list-item><list-item><p>Summarize the presenting signs and symptoms typically seen with hydroxyurea toxicity.</p></list-item><list-item><p>Review treatment strategies for hydroxyurea toxicity.</p></list-item><list-item><p>Explain the importance of improving care coordination amongst interprofessional team members to optimize outcomes for patients with hydroxyurea toxicity.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=275&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=275">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-275.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hydroxyurea is an antineoplastic agent used alone or in combination with other chemotherapeutic drugs or radiation in the treatment of resistant leukemias and carcinomas of the head and neck. It is also useful to increase fetal hemoglobin concentration, thus reducing the frequency of severe crisis and reducing the necessity for blood transfusions in patients with sickle cell anemia.</p>
        <p>They also use hydroxyurea off-label in the treatment of polycythemia vera, essential thrombocythemia, psoriasis, acute myeloid leukemia, meningioma, melanoma, and ovarian cancer.<xref ref-type="bibr" rid="article-275.r1">[1]</xref><xref ref-type="bibr" rid="article-275.r2">[2]</xref></p>
      </sec>
      <sec id="article-275.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Hydroxyurea is an extremely toxic drug with a low therapeutic index.</p>
        <p>Since hydroxyurea inhibits DNA synthesis, it can result in significant toxicity, including myelosuppression. Furthermore, inhibition of DNA synthesis without affecting RNA synthesis may result in red blood cells becoming megaloblastic.</p>
      </sec>
      <sec id="article-275.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Overdose data is limited, but case reports exist. One such case is an accidental overdose of hydroxyurea in a 2-year-old child resulted in mild myelosuppression.<xref ref-type="bibr" rid="article-275.r3">[3]</xref>&#x000a0;The clinicians observed the patient in the emergency department for 8 hours and then discharged home. They monitored blood counts for myelosuppression for two weeks as an outpatient.&#x000a0;</p>
        <p>In another case, a woman developed agitation, widespread myoclonic jerks, oculogyric crisis, sinus tachycardia, and myelosuppression after ingesting 60 grams of hydroxyurea.</p>
        <p>Another case series reported acute mucocutaneous toxicity in three patients with advanced acute myelogenous leukemia treated with oral high dose hydroxyurea at a dose of 10 grams for 8 to 10 days.<xref ref-type="bibr" rid="article-275.r4">[4]</xref> All three patients developed severe acute stomatitis. Two patients developed acute cutaneous toxicity associated with soreness, violet erythema, and edema of palms and soles, followed by intense hyperpigmentation of the skin.</p>
      </sec>
      <sec id="article-275.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Hydroxyurea is a hydroxylated analog of urea, inhibiting DNA synthesis by inhibiting ribonucleotide diphosphatase reductase and blocking the conversion of ribonucleotides to deoxyribonucleotides.<xref ref-type="bibr" rid="article-275.r5">[5]</xref><xref ref-type="bibr" rid="article-275.r6">[6]</xref></p>
        <p>Hydroxyurea is cell-cycle specific for the S phase, causing cell arrest at G1 to S.</p>
        <p>Hydroxyurea increases HbF levels by stimulating HbF production, but the exact mechanism of HbF production is unknown. It also has antioxidant properties, alters the RBC membrane, increases red blood cell (RBC) deformability by increasing intracellular water content, and decreases RBC adherence to the endothelium.<xref ref-type="bibr" rid="article-275.r7">[7]</xref><xref ref-type="bibr" rid="article-275.r8">[8]</xref><xref ref-type="bibr" rid="article-275.r9">[9]</xref></p>
      </sec>
      <sec id="article-275.s6" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>Hydroxyurea is administered orally, is readily absorbed, and has 100% bioavailability. The half-life is 1.9 to 3.9 hours in adults and 1.7 hours in children.<xref ref-type="bibr" rid="article-275.r10">[10]</xref><xref ref-type="bibr" rid="article-275.r11">[11]</xref></p>
        <p>Hydroxyurea is excreted in the urine with recommendations of dose change in patients with kidney function impairment.</p>
      </sec>
      <sec id="article-275.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>Hematology-Oncology</bold>
</p>
        <p>Bone marrow suppression: myelosuppression leads to anemia, leukopenia (more common), and thrombocytopenia. This toxicity is reversible by withholding the medication for two weeks and can potentially be resumed at a lower dose.</p>
        <p>Hydroxyurea causes macrocytosis, seen early in treatment, and may be confused with pernicious anemia. While unrelated to vitamin B12 or folic acid deficiency, prophylactic folic acid supplementation is the recommended intervention to assist with macrocytosis.<xref ref-type="bibr" rid="article-275.r12">[12]</xref></p>
        <p>Hydroxyurea used to manage myeloproliferative disorders can cause secondary leukemias.&#x000a0;A case series detailed three patients with essential thrombocythemia who were continuously receiving hydroxyurea for 47, 81, and 90 months had a leukemic transformation.<xref ref-type="bibr" rid="article-275.r13">[13]</xref></p>
        <p>Long-term use of hydroxyurea can cause skin cancer; cutaneous carcinomas are a severe side effect of hydroxyurea.<xref ref-type="bibr" rid="article-275.r14">[14]</xref> This condition can occur after several years of treatment with hydroxyurea. Patients on HU treatment need to be monitored and follow up for the long term.</p>
        <p>
<bold>Gastrointestinal</bold>
</p>
        <p>Hydroxyurea has correlations with gastric distress,&#x000a0;gastritis, mucositis, and oral mucosa ulcer.<xref ref-type="bibr" rid="article-275.r15">[15]</xref><xref ref-type="bibr" rid="article-275.r16">[16]</xref></p>
        <p>There are reports of elevation of serum concentrations of hepatic enzymes in patients receiving hydroxyurea. While rare, there are reports of hepatotoxicity resulting in fatal hepatic failure in patients with HIV infection receiving the drug in combination with antiretroviral agents. Fatal hepatotoxicity occurred most frequently in patients receiving combination therapy with hydroxyurea, didanosine, and stavudine.&#x000a0;</p>
        <p>Fatal and nonfatal pancreatitis has been reported in patients with HIV infection, during therapy with hydroxyurea and didanosine, with or without stavudine. In these patients, close monitoring of signs and symptoms of pancreatitis the recommendation, along with permanent discontinuation hydroxyurea in patients who develop signs and symptoms of pancreatitis.</p>
        <p>
<bold>Dermatology</bold>
</p>
        <p>Long-term treatment with hydroxyurea&#x000a0;is associated with painful skin ulcers, aphthous ulcers, non-ulcerative toxicity with erythema, and skin infiltration.<xref ref-type="bibr" rid="article-275.r17">[17]</xref> Rarely, long-term therapy with hydroxyurea is associated with gangrene of the toes and digits.<xref ref-type="bibr" rid="article-275.r18">[18]</xref><xref ref-type="bibr" rid="article-275.r19">[19]</xref> The recommendation is to discontinue the drug.</p>
        <p>
<bold>Reproductive</bold>
</p>
        <p>Hydroxyurea decreases sperm count and sperm motility in males and is considered pregnancy category D.&#x000a0;&#x000a0;Breastfeeding is not recommended during hydroxyurea treatment.<xref ref-type="bibr" rid="article-275.r20">[20]</xref></p>
        <p>
<bold>Pulmonary</bold>
</p>
        <p>Hydroxyurea can cause severe interstitial pneumonitis.<xref ref-type="bibr" rid="article-275.r21">[21]</xref> It can even occur after several years of initial treatment with hydroxyurea. If not diagnosed, drug-induced interstitial pneumonitis can lead to lung fibrosis and respiratory failure. The recommendation is to discontinue the drug.</p>
        <p>
<bold>Cardiology</bold>
</p>
        <p>There is a case reported in the literature, a patient with chronic myelogenous leukemia receiving hydroxyurea treatment who had an acute myocardial infarction. The pathogenesis of this adverse effect is unclear.<xref ref-type="bibr" rid="article-275.r22">[22]</xref></p>
        <p>
<bold>Neurology</bold>
</p>
        <p>Rare side effects include headache, dizziness, disorientation, hallucinations, and seizures.</p>
      </sec>
      <sec id="article-275.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>As with most medicines, patients on hydroxyurea should have their electrolytes and renal function monitored, especially in patients with severe nausea, vomiting, and diarrhea. For those with myelosuppression, the practitioner should monitor signs of infection as well as CBC with differential count and platelet counts.</p>
      </sec>
      <sec id="article-275.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pre-hospital GI decontamination is not recommended.</p>
          </list-item>
          <list-item>
            <p>Activated charcoal administration if an overdose is recent and patient, not vomiting, and able to maintain the airway.</p>
          </list-item>
          <list-item>
            <p>Airway management. Intubation in patients with severe respiratory symptoms.</p>
          </list-item>
        </list>
        <p>Treatment is symptomatic and supportive.</p>
        <p>In patients with nausea and vomiting, treat with antiemetics, and administer intravenous fluids as needed.</p>
        <p>In patients with myelosuppression, treat with colony-stimulating factors in patients with neutropenia, platelets transfusion in patients with severe thrombocytopenia, and packed red blood cell transfusion in patients with anemia.</p>
        <p>In patients with seizures, treat with antiepileptics.</p>
        <p>Mild mucositis treatment is with bland oral rinses like 0.9 % normal saline, sodium bicarbonate, and water. In moderate cases with pain, a local anesthetic is added. Treatment for moderate to severe mucositis is with local anesthetic and systemic analgesics. Oral antimicrobial mouthwashes can help to decrease the risk of infection.&#x000a0;</p>
      </sec>
      <sec id="article-275.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Myelosuppression and gastrointestinal side effects were present with other chemotherapeutic agents used in combination with hydroxyurea.&#x000a0;</p>
      </sec>
      <sec id="article-275.s11" sec-type="Consultations">
        <title>Consultations</title>
        <p>If there is any concern for hydroxyurea toxicity, consultation with poison control is recommended.</p>
      </sec>
      <sec id="article-275.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Hydroxyurea toxicity management requires an interprofessional team of healthcare professionals, including nursing staff, pharmacists, emergency medicine physicians, internists, and hematology-oncologist. Emergency medicine physicians should monitor for signs of respiratory depression and stabilize the patient&#x02019;s airway. Consultation with a medical toxicologist/and or contact the poison center in patients with an unclear diagnosis may be necessary. Hematologists care for inpatients. Critical care and oncology nurses monitor patients and notify the team of issues.</p>
        <p>Nurses and pharmacists should educate patients on the side effects of medication and signs of symptoms that require monitoring while taking the drug, and the pharmacist should work with the clinicians to perform medication reconciliation and verify the absence of drug-drug interactions. This interprofessional approach will lead to better outcomes in cases of hydroxyurea toxicity. [Level 5]</p>
      </sec>
      <sec id="article-275.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=275&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=275">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/hydroxyurea-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=275">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/275/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=275">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-275.s14">
        <title>References</title>
        <ref id="article-275.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finazzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barbui</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>How I treat patients with polycythemia vera.</article-title>
            <source>Blood</source>
            <year>2007</year>
            <month>Jun</month>
            <day>15</day>
            <volume>109</volume>
            <issue>12</issue>
            <fpage>5104</fpage>
            <page-range>5104-11</page-range>
            <pub-id pub-id-type="pmid">17264301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barbui</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Barosi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Grossi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gugliotta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liberato</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Marchetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mazzucconi</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Rodeghiero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tura</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.</article-title>
            <source>Haematologica</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>89</volume>
            <issue>2</issue>
            <fpage>215</fpage>
            <page-range>215-32</page-range>
            <pub-id pub-id-type="pmid">15003898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Rey</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Flanagan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fish</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>ZR</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Ware</surname>
                <given-names>RE</given-names>
              </name>
              <collab>BABY HUG Investigators</collab>
            </person-group>
            <article-title>Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2012</year>
            <month>Jul</month>
            <day>15</day>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>170</fpage>
            <page-range>170-2</page-range>
            <pub-id pub-id-type="pmid">21744485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brincker</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>BE</given-names>
              </name>
            </person-group>
            <article-title>Acute mucocutaneous toxicity following high-dose hydroxyurea.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>1993</year>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>496</fpage>
            <page-range>496-7</page-range>
            <pub-id pub-id-type="pmid">8258201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yarbro</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action of hydroxyurea.</article-title>
            <source>Semin Oncol</source>
            <year>1992</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>3 Suppl 9</issue>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">1641648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krakoff</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Reichard</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of ribonucleoside diphosphate reductase by hydroxyurea.</article-title>
            <source>Cancer Res</source>
            <year>1968</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>8</issue>
            <fpage>1559</fpage>
            <page-range>1559-65</page-range>
            <pub-id pub-id-type="pmid">4876978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rees</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Gladwin</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Sickle-cell disease.</article-title>
            <source>Lancet</source>
            <year>2010</year>
            <month>Dec</month>
            <day>11</day>
            <volume>376</volume>
            <issue>9757</issue>
            <fpage>2018</fpage>
            <page-range>2018-31</page-range>
            <pub-id pub-id-type="pmid">21131035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eridani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mosca</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Fetal hemoglobin reactivation and cell engineering in the treatment of sickle cell anemia.</article-title>
            <source>J Blood Med</source>
            <year>2011</year>
            <volume>2</volume>
            <fpage>23</fpage>
            <page-range>23-30</page-range>
            <pub-id pub-id-type="pmid">22287860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hankins</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aygun</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy in sickle cell disease--state of the art and future prospects.</article-title>
            <source>Br J Haematol</source>
            <year>2009</year>
            <month>May</month>
            <volume>145</volume>
            <issue>3</issue>
            <fpage>296</fpage>
            <page-range>296-308</page-range>
            <pub-id pub-id-type="pmid">19222472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ware</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Despotovic</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mortier</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Flanagan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smeltzer</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Kimble</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Aygun</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sparreboom</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.</article-title>
            <source>Blood</source>
            <year>2011</year>
            <month>Nov</month>
            <day>03</day>
            <volume>118</volume>
            <issue>18</issue>
            <fpage>4985</fpage>
            <page-range>4985-91</page-range>
            <pub-id pub-id-type="pmid">21876119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gwilt</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Tracewell</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics of hydroxyurea.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1998</year>
            <month>May</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>347</fpage>
            <page-range>347-58</page-range>
            <pub-id pub-id-type="pmid">9592619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Randi</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Ruzzon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Luzzatto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tezza</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Girolami</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fabris</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.</article-title>
            <source>Haematologica</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>90</volume>
            <issue>2</issue>
            <fpage>261</fpage>
            <page-range>261-2</page-range>
            <pub-id pub-id-type="pmid">15710584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liozon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brigaudeau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Trimoreau</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Desangles</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fermeaux</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Praloran</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bordessoule</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature.</article-title>
            <source>Hematol Cell Ther</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-8</page-range>
            <pub-id pub-id-type="pmid">9088933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Est&#x000e8;ve</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Georgescu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Heitzmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>[Multiple skin and mouth squamous cell carcinomas related to long-term treatment with hydroxyurea].</article-title>
            <source>Ann Dermatol Venereol</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>128</volume>
            <issue>8-9</issue>
            <fpage>919</fpage>
            <page-range>919-21</page-range>
            <pub-id pub-id-type="pmid">11590345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antonioli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Guglielmelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pieri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Finazzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rumi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Martinelli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vianelli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Luigia Randi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bertozzi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>De Stefano</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Za</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ruggeri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cacciola</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cacciola</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pogliani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rodeghiero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Baccarani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Passamonti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Finazzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rambaldi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bosi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cazzola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barbui</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vannucchi</surname>
                <given-names>AM</given-names>
              </name>
              <collab>AGIMM Investigators</collab>
            </person-group>
            <article-title>Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN.</article-title>
            <source>Am J Hematol</source>
            <year>2012</year>
            <month>May</month>
            <volume>87</volume>
            <issue>5</issue>
            <fpage>552</fpage>
            <page-range>552-4</page-range>
            <pub-id pub-id-type="pmid">22473827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hern&#x000e1;ndez-Boluda</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Alvarez-Larr&#x000e1;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Angona</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bellosillo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Avil&#x000e9;s</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Teruel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Besses</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia.</article-title>
            <source>Br J Haematol</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>152</volume>
            <issue>1</issue>
            <fpage>81</fpage>
            <page-range>81-8</page-range>
            <pub-id pub-id-type="pmid">21083657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Latagliata</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spadea</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cedrone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Giandomenico</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>De Muro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Villiv&#x000e0;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Breccia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anaclerico</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Porrini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spirito</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rago</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Avvisati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alimena</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Montanaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Andriani</surname>
                <given-names>A</given-names>
              </name>
              <collab>Gruppo Laziale SMPC Ph1 neg</collab>
            </person-group>
            <article-title>Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug.</article-title>
            <source>Cancer</source>
            <year>2012</year>
            <month>Jan</month>
            <day>15</day>
            <volume>118</volume>
            <issue>2</issue>
            <fpage>404</fpage>
            <page-range>404-9</page-range>
            <pub-id pub-id-type="pmid">21692060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kr&#x000e4;mer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hochhaus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krasniqi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hehlmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy.</article-title>
            <source>Ann Hematol</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>81</volume>
            <issue>8</issue>
            <fpage>467</fpage>
            <page-range>467-9</page-range>
            <pub-id pub-id-type="pmid">12224005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salmon-Ehr</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Leborgne</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vilque</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Potron</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>[Secondary cutaneous effects of hydroxyurea: prospective study of 26 patients from a dermatologic consultation].</article-title>
            <source>Rev Med Interne</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-4</page-range>
            <pub-id pub-id-type="pmid">10685452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berthaut</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Guignedoux</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kirsch-Noir</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>de Larouziere</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ravel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bachir</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Galact&#x000e9;ros</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ancel</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Kunstmann</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jouannet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Girot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mandelbaum</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males.</article-title>
            <source>Haematologica</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>93</volume>
            <issue>7</issue>
            <fpage>988</fpage>
            <page-range>988-93</page-range>
            <pub-id pub-id-type="pmid">18508803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Internullo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giannelli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sardo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Antonaglia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Villani</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Angelici</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Palange</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature.</article-title>
            <source>Eur Rev Med Pharmacol Sci</source>
            <year>2014</year>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>190</fpage>
            <page-range>190-3</page-range>
            <pub-id pub-id-type="pmid">24488907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-275.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000e4;lsch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wieneke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Erbel</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Acute myocardial infarction in a patient with chronic myelocytic leukemia during chemotherapy with hydroxyurea.</article-title>
            <source>Herz</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>420</fpage>
            <page-range>420-2</page-range>
            <pub-id pub-id-type="pmid">20721521</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
